Relative Bioavailability Study in Healthy Subjects to Evaluate the Pharmacokinetics of HTL0009936 After One Dose of Prototype Formulation

Status:
Completed

Trial end date:
2016-08-01

Target enrollment:

Participant gender:

The purpose of this study is to find a modified release oral tablet formulation for this drug, which will be safe and well tolerated.

Phase 1

Heptares Therapeutics Limited

Quotient Clinical